 |
38 Diseases |  |
10 Trials |
|
10 Trials |  |
381 News |  |
| 1234» |
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Sinapic acid-pullulan based inflammation responsive nanomicelles for the local treatment of experimental inflammatory arthritis. (Pubmed Central) - Sep 17, 2024
We have introduced Rebamipide (Reb)-loaded Sinapic acid (SA)-Pullulan (PL) nanomicelles (Reb@SA-PL NMs), a nanotechnology based drug delivery system for the treatment of inflammatory arthritis...Reb@SA-PL NMs prevented bone erosion, cartilage degradation, joint oedema, and synovial inflammation. The results of the study demonstrated that Reb@SA-PL NMs, an enzyme-responsive drug delivery system, has excellent potential for alleviating inflammatory arthritis by blocking MMP-13 and RANKL.
- || aspirin / Generic mfg.
Retrospective data, Review, Journal: Drugs Effective for Nonsteroidal Anti-inflammatory Drugs or Aspirin-induced Small Bowel Injuries: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (Pubmed Central) - Jul 15, 2024
The results of the study demonstrated that Reb@SA-PL NMs, an enzyme-responsive drug delivery system, has excellent potential for alleviating inflammatory arthritis by blocking MMP-13 and RANKL. Misoprostol was effective in treating SB injuries caused by NSAIDs or aspirin (CRD42023410946).
- | Fexuclue (fexuprazan) / Daewoong Pharma, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Efficacy of fexuprazan compared with rebamipide in Korean patients with gastritis: A matching-adjusted indirect comparison. (Pubmed Central) - Jul 12, 2024
Misoprostol was effective in treating SB injuries caused by NSAIDs or aspirin (CRD42023410946). The two-week fexuprazan treatment was superior to the two-week rebamipide treatment and similar to the four-week rebamipide treatment for patients with gastritis.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Observational data, Reimbursement, Retrospective data, Review, US reimbursement, Journal: DA-9601 has protective effects comparable to those of proton pump inhibitor and rebamipide against nonsteroidal anti-inflammatory drugs-induced upper and lower gastrointestinal bleeding in patients with rheumatoid arthritis: A nationwide study using Korean Health Insurance Review and Assessment Service database. (Pubmed Central) - Jul 5, 2024
In the multivariate Cox regression analysis, no significant difference was observed in lower and upper GI bleeding hazards between patients with RA using DA-9601, PPI, and rebamipide. Our results suggest that DA-9601 may exhibit protection against NSAIDs-induced GI bleeding that is comparable to those of PPI and rebamipide in patients with RA.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database. (Pubmed Central) - Jun 11, 2024
Our results suggest that DA-9601 may exhibit protection against NSAIDs-induced GI bleeding that is comparable to those of PPI and rebamipide in patients with RA. Continuous co-prescription of rebamipide significantly reduced the risk of upper gastrointestinal bleeding in an Asian cohort of new users of NSAIDs with osteoarthritis or low back pain without risk factors other than age.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Clinical Trial,Phase III, Journal: Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial). (Pubmed Central) - Jun 2, 2024
P3
Rebamipide mouthwash was as beneficial as benzydamine mouthwash in minimizing the incidence of severe oral mucositis induced by treatment of head and neck cancer. However, rebamipide gargle proved to be superior to benzydamine in terms of reduction in the severity of the radiation-induced oral mucositis.
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
REBAMIPIDE ATTENUATES RENAL MANIFESTATIONS VIA ANTIOXIDANT EFFECTS ON PODOCYTES IN AN ANIMAL MODEL FOR SYSTEMIC LUPUS ERYTHEMATOSUS () - May 29, 2024 - Abstract #EULAR2024EULAR_3303;
However, rebamipide gargle proved to be superior to benzydamine in terms of reduction in the severity of the radiation-induced oral mucositis. Rebamipide could be considered as one of the adjunctive treatment options in managing renal manifestations in lupus according to the present results from lupus-prone mice.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: EVALUATION OF THE EFFECT OF REBAMIPIDE ON THE PROGRESSION OF ULCERATIVE COLITIS IN RATS IN THE EXPERIMENT. (Pubmed Central) - May 29, 2024
Due to the presence of these properties, it is hypothesized that rebamipide may have a protective effect on the intestinal mucosa during prolonged inflammation, making it a promising candidate for inclusion in therapeutic strategies for ulcerative colitis. The results of this study suggest that rebamipide holds potential therapeutic benefits for the treatment of ulcerative colitis.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: High-Performance Liquid Chromatography (HPLC) Method Validation for Identifying and Quantifying Rebamipide in Ethosomes. (Pubmed Central) - Apr 15, 2024
The results underscore the method's specificity, accuracy, and precision within the specified concentration range. Overall, the validated method contributes to the advancement of ocular drug delivery systems, providing a reliable analytical tool for pharmaceutical research.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
COMPARISON OF EFFECTS OF TEGOPRAZAN AND REBAMIPIDE COMBINATION THERAPY AND TEGOPRAZAN MONOTHERAPY ON THE HEALING OF ENDOSCOPIC SUBMUCOSAL DISSECTION-INDUCED GASTRIC ULCER: A RANDOMIZED-CONTROLLED, MULTICENTER STUDY (154AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4302;
A total of 132 lesions and 121 lesions were included in the modified intention-to-treat (mITT) and per-protocol analyses, respectively. The ulcer healing rate at 4 weeks (96.4 % vs. 93.5%, P=0.02 in the mITT analysis) was significantly higher in the combination group than tegoprazan monotherapy group, and combination therapy was a significant predictor for the higher than mean ulcer healing at 4 weeks (OR 2.28, 95% CI 1.04-5.02, P=0.04).
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors. (Pubmed Central) - Mar 12, 2024
: Rebamipide, like PPIs, was highly effective in preventing blood hemoglobin level decreases, as shown in real-world data. Rebamipide could be a comprehensive strategy for protecting the entire GI tract, especially when considering PPIs' potential side effects on the lower GI tract.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Rebamipide and Derivatives are Potent, Selective Inhibitors of Histidine Phosphatase Activity of the Suppressor of T Cell Receptor Signaling Proteins. (Pubmed Central) - Jan 22, 2024
Although rebamipide has poor cell permeability, we demonstrated that a liposomal preparation can inactivate the phosphatase activity of Sts-1 in cells. These studies demonstrate that Sts-1 enzyme activity can be pharmacologically inactivated and provide foundational tools and insights for the development of immune-enhancing therapies that target the Sts proteins.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 16, 2024
P1/2, N=50, Recruiting, Sponsor: October 6 University
These studies demonstrate that Sts-1 enzyme activity can be pharmacologically inactivated and provide foundational tools and insights for the development of immune-enhancing therapies that target the Sts proteins. Not yet recruiting --> Recruiting | N=100 --> 50 | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: Feb 2023 --> Oct 2024
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
The ShuGanAnWei formula inhibited NSAIDs induced gastrointestinal inflammation and injury (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_2130;
Not yet recruiting --> Recruiting | N=100 --> 50 | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: Feb 2023 --> Oct 2024 Our study suggested that the preventive treatment of SGAW is beneficial in reducing the occurrence of NSAIDs induced gastrointestinal injury, with efficacy similar to that of rebamipide.
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Efficacy of Rebamipide in the Prevention of Aspirin Or Nsaid-Induced Gastrointestinal Mucosal Injury () - Jan 6, 2024 - Abstract #APASL2024APASL_1759;
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P1/2 trial: Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease (clinicaltrials.gov) - Oct 15, 2023
P1/2, N=40, Not yet recruiting, Sponsor: Cairo University
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. (Pubmed Central) - Sep 28, 2023
In conclusion, rebamipide improves the intestinal barrier condition and symptoms in D-IBSoFD. The rebamipide effects are not inferior to those of trimebutine.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment open, Trial completion date, Trial primary completion date: Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Sep 21, 2023
P3, N=39, Recruiting, Sponsor: Cairo University
The rebamipide effects are not inferior to those of trimebutine. Not yet recruiting --> Recruiting | Trial completion date: Nov 2021 --> Dec 2023 | Trial primary completion date: Nov 2021 --> Dec 2023
- | Aphthasol (amlexanox) / Abeona Therap, Esteve, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Management of Recurrent Aphthous Stomatitis: An Indian Expert Consensus. (Pubmed Central) - Aug 28, 2023
Topical and systemic agents can be used in combination for effective relief. In conclusion, this consensus will help physicians and may harmonize effective diagnosis and treatment of RAS.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
PK/PD data, Journal: Determination of rebamipide in human plasma by a validated liquid chromatography-tandem mass spectrometry: Application in pharmacokinetics research. (Pubmed Central) - Aug 22, 2023
The CV% values of the inter and intra batch precision of the method were both less than 15.0%. This method has been successfully applied to pharmacokinetic studies to evaluate the main pharmacokinetic parameters of rebamipide.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal, IO biomarker: Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/?-catenin/FOXO1and NF?B signaling. (Pubmed Central) - Jun 1, 2023
This method has been successfully applied to pharmacokinetic studies to evaluate the main pharmacokinetic parameters of rebamipide. Thirty-two male Wistar albino rats were randomized into four groups: G1 (sham): rats were subjected to surgical stress without I/R, GII (I/R): rats were subjected to 60
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang, Tivicay (dolutegravir) / ViiV Healthcare
FDA event, Preclinical, Journal: Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study. (Pubmed Central) - May 22, 2023
Visualizations of the intermolecular interactions of Dolutegravir in the active sites of MAO-B and AChE revealed the formation of several stable hydrogen bonds. Overall, Dolutegravir was identified as a potential anti-AD drug, however further in vivo evaluations should be considered.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, PK/PD data, Review, Journal: Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review (Pubmed Central) - May 15, 2023
The review article is about the main pharmacokinetic and pharmacodynamic characteristics of rebamipide. A detailed understanding of pharmacodynamics and pharmacokinetics allows for individual selection of therapy based on the characteristics of the patient's body - gender, age, comorbidities; choose the optimal route of administration and dosing regimen; predict adverse effects and drug interactions; be determined with new clinical indications.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: The effect of the FODMAP and rebamipid diet on the activity of disaccharidases in patients with enteropathy with impaired membrane digestion (Pubmed Central) - May 15, 2023
The clinical symptoms of fermentable carbohydrate intolerance and increased membrane enzyme activity are reduced by a low FODMAP diet in patients with ENMT, but clinical symptoms of food intolerance reappear when switching to a normal diet. Treatment with rebamipide improves food tolerance and consistently increases the activity of TSOTS enzymes after 4 and 8 weeks.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. (Pubmed Central) - Apr 28, 2023
In conclusion, the present findings suggest that the promising ameliorative features of rebamipide against experimental colitis were driven by combating the colonic inflammatory and oxidative responses. In perspective, augmentation of colonic SIRT1/FoxO3a/Nrf2 and inhibition of PI3K/AKT pathways were engaged in the observed favorable outcomes.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
PK/PD data, Journal: Immediate-release tablet formulation of rebamipide and a pharmacokinetic study in healthy human subjects. (Pubmed Central) - Mar 28, 2023
Despite similar in vitro dissolution profiles, in vivo pharmacokinetic results revealed a partial difference between F4 and reference tablets. Thus, further study on formulation development is still needed.
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Carafate (sucralfate) / AbbVie, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
THE EFFECTS OF REBAMIPIDE, SUCRALFATE AND RIFAXIMIN AGAINST INFLAMMATION AND APOPTOSIS IN RADIATION-INDUCED INTESTINAL INJURY OF MICE (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_2990;
This experimental research demonstrates that rebamipide, sucralfate, and rifaximin can suppress acute IR-induced inflammation and apoptosis via up-regulation of Sirt1 expression through NAMPT-mediated NAD + biosynthesis and down-regulation of the NF-?B/MAPK signaling pathway in the large and small intestines of mice. Rebamipide, sucralfate, and rifaximin may be clinically a candidate for the preventive strategy of radiation enterocolitis.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Evaluation of 5% Amlexenox Oral Paste and Rebamipide Tablets in Treatment of Recurrent Apthous Stomatitis and Comparison with Dologel CT. (Pubmed Central) - Feb 7, 2023
However, 5% oral Amlexanox paste and Rebamipide tablets are more efficacious in the treatment of RAS and tend to heal the ulcer at a more accelerated pace. Our research concluded that 5% oral Amlexanox paste and Rebamipide tablets tend to heal the ulcer at a more accelerated pace as compared to Dologel CT.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
PK/PD data, Journal: Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. (Pubmed Central) - Jan 22, 2023
The plasma concentration of rebamipide after administration of SA001 was higher with a dose adjusted AUC and C 2.20 and 5.45 times higher in the 240 mg dose group and 4.73 and 11.94 times higher in the 600 mg dose group compared to conventional rebamipide. The favorable PK and tolerability profiles support further clinical development.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal, Immune cell: Rebamipide treatment ameliorates obesity phenotype by regulation of immune cells and adipocytes. (Pubmed Central) - Dec 28, 2022
Additionally, rebamipide addition inhibited adipocyte differentiation in 3T3-L1 cell lines. Taken together, our study demonstrates that rebamipide treatment is a novel and effective method to prevent diet-induced obesity.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease. (Pubmed Central) - Nov 23, 2022
The 4 groups exhibited no significant differences in the incidence of MACEs (P > 0.05). For patients age over 60 receiving DAPT following PCI in our study population, treatment with rabeprazole or a combination of rabeprazole and rebamipide could reduce the risk of upper gastrointestinal hemorrhage, as well as reduce its severity.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study. (Pubmed Central) - Nov 21, 2022
Although statistically significant differences were not generated, possibly as a result of the small sample size, mucosal breaks observed via capsule endoscopy revealed that rebamipide was likely to be more effective than lansoprazole in preventing small intestine damage caused by NSAIDs. Furthermore, fewer side-effects emerged with rebamipide.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Analysis of absorption-enhancing mechanisms for combinatorial use of spermine with sodium taurocholate in Caco-2 cells. (Pubmed Central) - Nov 16, 2022
Previously, we reported that the combined use of spermine (SPM) and sodium taurocholate (STC) (SPM-STC) significantly improves the oral absorption of rebamipide (BCS class IV) and pulmonary absorption of interferon-α without any harmful histopathological changes in the gastrointestinal tract and lungs, respectively...The rearrangement of tight junction-constituting proteins induced through the MAPK pathway has also been suggested as a possible mechanism for opening tight junctions. Claudin-4, a key protein constituting the tight junction, merged with F-actin along with the plasma membrane, was significantly decreased, which would be at least partial structural evidence for the tight-junction opening.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Erosive and ulcerative lesions of the digestive tract: optimization of diagnosis and management tactics (Pubmed Central) - Nov 2, 2022
One of them is Rebamipid-CZ, which has a fairly high safety and efficacy profile. It seems important to consider the issues of optimizing the prevention and treatment of erosive and ulcerative lesions of various parts of the gastrointestinal tract of various etiologies, taking into account the possibility of using rebamipide both as part of complex therapy and in isolation.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians (Pubmed Central) - Nov 2, 2022
Such main groups of epithelial protective drugs as proton pump inhibitors, bismuth drugs and probiotics are discussed in these Guidelines from the positions of evidence-based medicine. The clinical and pharmacological characteristics of such a universal epithelial protector as rebamipide, acting at the preepithelial, epithelial and subepithelial levels, throughout gastrointestinal tract, are presented in detail.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus. (Pubmed Central) - Oct 18, 2022
Reduction in symptom scores was also comparable between subgroups. Our findings suggest that efficacy of topical rebamipide is comparable to topical cyclosporine and tacrolimus for managing moderate to severe VKC and it merits further evaluation as a novel steroid sparing alternative for this disorder.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin. (Pubmed Central) - Oct 12, 2022
SSc hu-mice treated with rebamipide and other potential Th17-cell-modulating drugs presented significantly reduced tissue fibrosis. Mice injected with patient-derived PBMCs show promise as an animal model of SSc.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang, Amitiza (lubiprostone) / Takeda, Mallinckrodt
Journal: Combinational Approaches Targeting Various Aspects Involved in Intestinal Barrier Dysfunction-Induced Anxiety. (Pubmed Central) - Sep 4, 2022
Tight junction proteins, the epithelial barrier, the mucosal membrane, the Toll-like receptor/Myeloid differentiation factor 88 pathway, the activated immune system, and the HPA axis could all be potential targets for anxiety caused by intestinal barrier disruption. Quercetin and Rebamipide, Berberine and Agomelatine, Angiotensin II receptor type 1 blockers, and Lubiprostone can act on these targets to provide an anxiolytic effect.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial. (Pubmed Central) - Aug 25, 2022
Quercetin and Rebamipide, Berberine and Agomelatine, Angiotensin II receptor type 1 blockers, and Lubiprostone can act on these targets to provide an anxiolytic effect. These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal, IO biomarker: Further insights into the impact of rebamipide on gentamicin-induced nephrotoxicity in rats: modulation of SIRT1 and β-catenin/cyclin D1 pathways. (Pubmed Central) - Jul 29, 2022
Additionally, RBM alleviated the GM-induced deleterious kidney tissue histopathology. In conclusion, our findings have verified that RBM can halt GM-induced renal injury by partly modulating SIRT1 and β-catenin pathways.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Oral Corticosteroids Impair Mucin Production and Alter the Posttransplantation Microbiota in the Gut. (Pubmed Central) - Jul 8, 2022
In conclusion, our findings have verified that RBM can halt GM-induced renal injury by partly modulating SIRT1 and β-catenin pathways. Colonic mucin controlled the gut microbiota composition, and oral corticosteroid treatment modified the gut microbiota partly by reducing the colonic mucin.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. (Pubmed Central) - Jun 9, 2022
Colonic mucin controlled the gut microbiota composition, and oral corticosteroid treatment modified the gut microbiota partly by reducing the colonic mucin. This study demonstrated that the administration of rebamipide improves AG and IM in the antrum, especially in patients with HP non-infection (KCT0001915).
- ||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal, Adverse events: Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease. (Pubmed Central) - May 21, 2022
These AEs were not serious and occurred within 2-9 days. This study identified possible AEs of rebamipide, a relatively safe drug.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Electrostatic molecular effect of differently charged surfactants on the solubilization capacity and physicochemical properties of salt-caged nanosuspensions containing pH-dependent and poorly water-soluble rebamipide. (Pubmed Central) - Apr 29, 2022
In contrast, the negatively charged SLS did not significantly change the physicochemical properties of the salt-caged NSP. For example, the dissolution rate of the salt-caged NSP containing SLS in DW or pH 1.2 gastric fluid remained over 90% for 2 h. Surfactants for the formulation or dissolution media should be chosen carefully because of their effect on the physicochemical properties and solubilization capacity of salt-caged NSPs containing poorly water-soluble and ionizable drugs via electrostatic molecular interactions.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Design and evaluation of in vivo bioavailability in beagle dogs of bilayer tablet consisting of immediate release nanosuspension and sustained release layers of rebamipide. (Pubmed Central) - Apr 29, 2022
Unexpectedly, despite enhanced dissolution rate in a controlled manner, a designed bilayer tablet had no dose- and dosage form dependent in vivo bioavailability in beagle dogs as compared with IR 100 mg RBM reference tablet. It was evident that solubility in low pH condition, gastric residence time and absorption site of RBM should be carefully considered for designing specific SR or gastroretentive dosage form to improve therapeutic outcomes.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Intra-Articular Injection of Rebamipide-Loaded Nanoparticles Attenuate Disease Progression and Joint Destruction in Osteoarthritis Rat Model: A Pilot Study. (Pubmed Central) - Apr 23, 2022
It was evident that solubility in low pH condition, gastric residence time and absorption site of RBM should be carefully considered for designing specific SR or gastroretentive dosage form to improve therapeutic outcomes. Using a chemically induced rat model of OA, intra-articular delivery of rebamipide was associated with decreased local and systemic inflammatory response decreased joint degradation and arthritic progression.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Rebamipide attenuates alcohol-induced gastric epithelial cell injury by inhibiting endoplasmic reticulum stress and activating autophagy-related proteins. (Pubmed Central) - Apr 13, 2022
In the present study, molecular evidence of rebamipide inhibition of ERS and regulation of the protein expression of autophagy pathway components were produced using an acute alcoholic gastric mucosal injury model. This model provides a new approach for investigating the effects of rebamipide treatment on alcohol-induced gastric mucosal damage.
- ||| rebamipide mofetil (SA001) / Samjin Pharma
New P1 trial: Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers (clinicaltrials.gov) - Mar 31, 2022
P1, N=56, Completed, Sponsor: Samjin Pharmaceutical Co., Ltd.
- | temozolomide / Generic mfg.
Journal: Descriptors for some Compounds with Pharmacological Activity; Calculation of Properties. (Pubmed Central) - Mar 23, 2022
Abraham model solute descriptors have been determined for nisoldipine, nizatidine, loratadine, zonisamide, oxaprozin, rebamipide, domperidone, temozolomide, 'florfenicol', florfenicol A, dapsone, chrysin, benorilate, β-lapachone, and Ipriflavone based on published partition coefficients, molar solubilities and gas chromatographic retention indices. The calculated solute descriptors, combined with our previously published Abraham model correlations, are used to predict several important physicochemical and biological properties, such as air-water, air-blood, air-lung, air-fat, air-skin, water-lipid, water-membrane and water-skin partition coefficients, as well as permeation from water through skin.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Rebamipide as a Potential Alternative Gastroprotective Agent to Proton Pump Inhibitor in Elderly Chronic Nonsteroidal Anti-Inflammatory Drug Users without Risk Factors. (Pubmed Central) - Mar 19, 2022
However, elderly patients with other risk factors should use PPI rather than rebamipide. Therefore, the presence of GI risk factors needs to be evaluated in elderly chronic tNSAID users to prescribe the most suitable GPA in clinical practice.